of the Warrants. Vivo Asia Opportunity, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P. The address of the selling shareholder is 192 Lytton Avenue, Palo Alto, CA 94301.
(6)
The number reported under “Shares Beneficially Owned Prior to Offering” consists of (i) 9,263,890 ordinary shares and (ii) 2,988,115 ordinary shares issuable upon exercise of the Warrants. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Co-Invest, L.P. The address of the selling shareholder is 192 Lytton Avenue, Palo Alto, CA 94301.
(7)
The number reported under “Shares Beneficially Owned Prior to Offering” consists of (i) 15,194,445 ordinary shares and (ii) 4,901,040 ordinary shares issuable upon exercise of the Warrants. TCG Crossover GP, LLC (“TCG Crossover”) is the investment manager of TCG Crossover Fund I, L.P. and may be deemed to have sole voting and dispositive power over the shares held by TCG Crossover Fund I, L.P. The address of the selling shareholder is 705 High St., Palo Alto, CA 94301.
(8)
The number reported under “Shares Beneficially Owned Prior to Offering” consists of (a) (i) 368,560 ordinary shares, (ii) 774,540 ordinary shares and (iii) 249,830 ordinary shares issuable upon exercise of the Warrants held directly by 667, L.P. (“667”) and (b) (i) 4,631,440 ordinary shares, (ii) 9,625,460 ordinary shares and (iii) 3,104,740 ordinary shares issuable upon exercise of the Warrants held by Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Baker Funds”). Baker Bros. Advisors LP (“the Adviser”) is the investment adviser to the Baker Funds and has the sole voting and investment power with respect to the securities held by the Baker Funds and thus may be deemed to beneficially own such securities. Baker Bros. Advisors (GP) LLC (the “Adviser GP”) is the sole general partner of the Adviser and thus may be deemed to beneficially own the securities held by the Baker Funds. The managing members of the Adviser GP are Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the Baker Funds. Julian C. Baker, Felix J. Baker, the Adviser and the Adviser GP disclaim beneficial ownership of all shares held by the Baker Funds, except to the extent of their indirect pecuniary interest therein. The business address of the Adviser, the Adviser GP, Julian C. Baker and Felix J. Baker is 860 Washington Street, 3rd Floor, New York, NY 10014.
(9)
The number reported under “Shares Beneficially Owned Prior to Offering” consists of (i) 8,400,000 ordinary shares and (ii) 2,709,460 ordinary shares issuable upon exercise of the Warrants. Janus Capital Management LLC (“Janus”), an investment adviser registered under the Investment Advisers Act of 1940, acts as investment adviser for Janus Henderson Biotech Innovation Master Fund Limited (“JHBIF”) and has the ability to make decisions with respect to the voting and disposition of the shares. Under the terms of its management contract with JHBIF, Janus has overall responsibility for directing the investments of JHBIF in accordance with its investment objective, policies and limitations. JHBIF has one or more portfolio managers appointed by and serving at the pleasure of Janus to make decisions with respect to the voting and disposition of the shares. The address of each of JHBIF and Janus is 151 Detroit Street, Denver, Colorado 80206.
(10)
The number reported under “Shares Beneficially Owned Prior to Offering” consists of (i) 6,875,000 ordinary shares and (ii) 2,217,565 ordinary shares issuable upon exercise of the Warrants. The natural persons who make investment decisions with respect to the shares of the Company held by Pivotal bioVenture Partners Fund II, L.P. (“Fund II”), are the members of the Executive Committee of Nan Fung Group Holdings Limited (“NFGHL”), the indirect beneficial owner of the general partner of Fund II. The members of the NFGHL Executive Committee are Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, and Mr. Chun Wai Nelson Tang. The address of Pivotal bioVenture Partners Fund II, L.P. is Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, KY 1-1111, Cayman Islands.
(11)
The number reported under “Shares Beneficially Owned Prior to Offering” consists of (a) 1,116,575 ordinary shares, (b) (i) 1,530,000 ordinary shares and (ii) 493,510 ordinary shares issuable upon exercise of the Warrants. Sio Capital Management, LLC serves as investment advisor of Sio Partners LP. Sio GP, LLC is the general partner of Sio Partners LP. Michael Castor, as principal of Sio GP, LLC, has voting and investment control over the securities beneficially owned by Sio Partners LP. Each of Sio Capital Management, LLC, Sio GP, LLC and Michael Castor disclaims beneficial ownership over the securities held of record by Sio Partners LP, except to the extent of its or his pecuniary interest therein. The address for Sio Partners LP is 600 Third Avenue, 2nd Floor, New York, New York 10016.